UCB to unveil new data for RYSTIGGO®▼and ZILBRYSQ®▼ for gMG at the 2025 AANEM Annual Meeting and MGFA Scientific Session

• UCB will showcase 18 abstracts, including an oral presentation, demonstrating continued commitment to advancing targeted treatments for generalized Myasthenia Gravis (gMG).
• Presentations include new post hoc analyses considering corticosteroid dose tapering during treatment with RYSTIGGO^®▼ (rozanolixizumab)¹ and the impact of ZILBRYSQ^®▼ (zilucoplan) on Myasthenia Gravis Quality of Life 15-revised (MG-QoL15r) items.² 

Brussels (Belgium), 29 Oct 2025, 07:00 (CET) UCB (Euronext Brussels: UCB), a global biopharmaceutical company, today announced that it will be presenting new data highlighting insights on patient outcomes with rozanolixizumab and zilucoplan for the treatment of generalized Myasthenia Gravis (gMG) at the 2025 American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM) Annual Meeting and Myasthenia Gravis Foundation of America (MGFA) Scientific Session, taking place between October 29 – November 1, 2025, San Francisco, USA.

A total of 18 abstracts will be presented at AANEM and the MGFA scientific session, highlighting UCB’s dedication to driving advancements in gMG treatment. These presentations will cover data on rozanolixizumab and zilucoplan, including new insights on corticosteroid-sparing strategies and quality of life improvements, and long-term safety and effectiveness data. Additionally, insights from a real-world study on user characteristics and adherence patterns from the HumaMG app will be shared, reinforcing UCB’s commitment to improving gMG management. 

"Empowering patients with innovative solutions is at the core our purpose at UCB," said Donatello Crocetta, Global Head of Medical Affairs & Chief Medical Officer at UCB. "Our presentations at the AANEM Annual Meeting and MGFA Scientific Session showcase our focus on developing treatment options that not only highlight clinical management but also quality of life, providing meaningful outcomes that make a difference for those living with gMG."

"At UCB, we are deeply proud to present a robust range of data at this year’s AANEM Annual Meeting and MGFA Scientific Session, demonstrating our commitment to elevating the lives of patients with gMG through shared decision-making and continuous collaboration with healthcare professionals,” added Kimberly, Moran, PhD, MBA, SVP & Head, US Rare Diseases. "People living with gMG face unpredictable symptoms that can greatly impact their ability to perform daily activities. Expanding the body of evidence generation of the risks and benefits of our gMG targeted therapies is central to our mission of delivering meaningful, sustainable clinical improvements to address the unique challenges these patients encounter.”

Key UCB scientific and real-world data to be presented at AANEM and the MGFA Scientific Session 
include: 

• An oral presentation focusing on data from the double-blind Phase 3 MycarinG study and its open-label extensions (OLE) including a comprehensive analysis of corticosteroid dose tapering during treatment with rozanolixizumab in patients with gMG.¹ 
• A new and comprehensive analysis of treatment response from the Phase 3 MycarinG study and its open-label extensions offering valuable information on efficacy of rozanolixizumab in a clinical setting.³ 
• Data from a further analysis of the Phase 3 MycarinG study explores the long-term safety of cyclic rozanolixizumab treatment in patients with generalized Myasthenia Gravis (gMG) to evaluate its potential for sustained therapeutic use.⁴ 
• Post hoc data from the Phase 3 RAISE-XT trial examining zilucoplan's impact on health-related quality-of-life items, including more severe ones such as difficulty speaking.² 
• New data on the long-term effectiveness of zilucoplan, focusing on severe exacerbations in gMG based on predictive modeling from the Phase 3 RAISE and RAISE-XT clinical trial and a U.S. real-world database.⁵ 
• From the RAISE-XT 120-week follow-up, new post-hoc data looking at the long-term effect of zilucoplan treatment on fatigue.⁶ 
• An analysis exploring user characteristics and adherence patterns among individuals living with Myasthenia Gravis (MG), leveraging data from the HumaMG app to provide valuable real-world insights into patient management and engagement.⁷ 

UCB is also hosting a panel discussion entitled ‘Continuing the Conversation - Subpopulations with Barriers to Care in Myasthenia Gravis’ on October 29, 2025. There will also be a UCB-sponsored Industry Therapeutic Update on expert perspectives on two targeted generalized myasthenia gravis treatments on October 31, 2025.

Faces of MG

To further shine a light on MG, UCB is collaborating with the MG community on the recently launched ‘Faces of MG’ campaign, seeking to elevate the voices of those deeply connected to the disease and to foster understanding of the invisible impact it has on people’s lives. Learn more:   
https://www.ucb.com/solutions/diseases/myasthenia-gravis/faces-of-MG.